Clinical trial · Interventional
Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer
NCT02861196CI-TRIAL-00048938completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research aims to explore the therapeutic effect of neoadjuvant chemotherapy in muscular invasive bladder cancer of T2-4aN0M0, and the survival effect of combined-modality treatment model，then to clarify the probability of bladder preservation, corresponding cancer specific survival, and the quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intensity modulated radiation therapy, Radical cystectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Therapy Arm
- description
- Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
- interventionNames
- Procedure: Intensity modulated radiation therapy, Radical cystectomy
Primary outcomes (1)
- measure
- bladder preservation rate
- timeFrame
- 3 years
- description
- bladder preservation rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. bladder urothelium carcinoma 2. cT2-4aN0M0 3. life expectancy≥1 year 4. ECOG PS 0-1 5. have no previously received radiotherapy or chemotherapy 6. have no major organ dysfunction 7. have been provided informed written consent Exclusion Criteria: 1. extensive carcinoma in situ or ureter invaded 2. distant metastasis at primary diagnosis or lymphatic metastasis according to clinical diagnosis 3. have severe major organ dysfunction 4. cannot finish treatments because of other severe diseases or life expectance≤6 months 5. exist other malignant tumors 6. have severe coagulation disorders 7. no other trails participated in 4 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.